#Ockham cro full

Ockham also plans to use the acquisition to expand its FSP into clinical, which is Nexus’ specialty. “As a result, we’ve created this nice niche where, at the end of the day, we’ve become known as one of the top five early-stage oncology CROs.” “The small trials we work on require a certain amount of leadership, and the large guys can’t do that as efficiently as we do,” he said. Ockham and Nexus both compete with other small, oncology-focused CROs including Novella, Aptiv and Premier, said Baker. The company stayed with the market segment Ockham had been serving: emerging biotech and pharma companies seeking help with phase I and II trials. In 2009, said Baker, the company acquired five-year-old Ockham, a “distressed” full-service CRO with 60 employees. Over time, it began working with pharma companies, providing CRAs, data managers, statistical programmers and biostatisticians, and eventually offering functional service provider (FSP) services to companies working on cancer drugs. Ockham launched in 1986 as ASG, a specialty staffing company focusing primarily on IT. But Baker said by yearend Ockham will make a final decision on the combined entity’s name. LONDON and WILMINGTON, North Carolina and CARY, North Carolina, J/PRNewswire/ - Chiltern and Ockham, two leading full-service contract research organizations (CROs), today announce. For now, Nexus Oncology will be known as Nexus Oncology, an Ockham Company. Nexus founder Clare Wareing will stay as chief scientific officer. Ockham had 175 employees before the acquisition and operated primarily in the U.S., with satellite offices in India and the U.K. Twelve-year-old Nexus has 120 employees across Scotland, Poland, France, Germany, Sweden, Switzerland, Hungary, Belgium and Spain, in addition to Canada and the U.S. James Baker, Ockham’s CEO, said Nexus comes with a stable book of business and an institutional investment partner. Terms of the cash-and-stock deal were undisclosed. Ockham Development Group of Cary, N.C., has acquired Nexus Oncology of Edinburgh, Scotland. in Zoology-PreMed from Northern Arizona University and a Masters in Health Administration from the University of Washington School of Public Health.Two small but powerful oncology-focused CROs are now one. DJ Cro thumbnail DJ Cro This albums like eating a high fiber diet.good shit. Jessica earned a Certificate in Clinical Trials, Design, and Management from UCSD, as well as holds a B.S. From 2009 to 2012, Jessica also served as a facilitator for the University of Liverpool online Masters of Science in Clinical Research programme, where she taught the Information and Data Management course. Throughout these positions, Jessica was responsible for the operational delivery of data management activities in multiple Phase I-III clinical programs with indications in Oncology, Endocrinology, Ophthalmology, Cardiology, CNS, Respiratory, and Gastroenterology.

#Ockham cro full

Before Ascenta, Jessica held positions of increasing responsibility at Isis Pharmaceuticals where she saw the department go from one of full in-house data management capabilities to then being the only person in data management and overseeing all of the outsourcing of their studies. She also served as Senior Manager of Clinical Data Management at Ascenta Therapeutics, an early stage Oncology drug development company. Prior to joining DNS, Jessica was a Data Management consultant to Phenomix Corporation and MacuSight, and Associate Director of Clinical Data Management at Ockham Development Group, a small North Carolina based CRO for which she opened a Data Management office in San Diego.

Jessica joined DNS (formerly Helicon Therapeutics) in May 2010, bringing 12 years of experience in clinical data management at both CROs and small Biotech/Pharma, in both management and non-management roles.

Jessica Berrett is Director of Clinical Data Management.